| Literature DB >> 12241891 |
Karl Claxton1, Mark Sculpher, Michael Drummond.
Abstract
Regulatory and reimbursement authorities face uncertain choices when considering the adoption of health-care technologies. In this Viewpoint, we present an analytic framework that separates the issue of whether a technology should be adopted on the basis of existing evidence from whether more research should be demanded to support future decisions. We show the application of this framework to the assessment of heath-care technologies using a published analysis of a new drug treatment for Alzheimer's disease. The results of the analysis show that the amount and type of evidence required to support the adoption of a health technology will differ substantially between technologies with different characteristics. Additionally, the analysis can be used to aid the efficient design of research. We discuss the implications of adoption of this new framework for regulatory and reimbursement decisions.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12241891 DOI: 10.1016/S0140-6736(02)09832-X
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321